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Interleukin-33 produced by M2 
macrophages and other immune 
cells contributes to Th2 immune 
reaction of IgG4-related disease
Sachiko Furukawa1, Masafumi Moriyama1,2, Kensuke Miyake3, Hitoshi Nakashima4, 
Akihiko Tanaka1, Takashi Maehara1, Mana Iizuka-Koga5,6, Hiroto Tsuboi5, Jun-
Nosuke Hayashida1, Noriko Ishiguro1, Masaki Yamauchi1, Takayuki Sumida5 & 
Seiji Nakamura1
IgG4-related disease (IgG4-RD) is characterized by elevated serum IgG4 and marked infiltration of 
IgG4-positive cells in multiple organs. Interleukin-33 (IL-33) is a recently described cytokine that is 
secreted by damaged epithelial cells, macrophages, and dendritic cells, and potently activates helper T 
type 2 (Th2) immune responses, which have been suggested to play a major role in IgG4 production of 
IgG4-RD. Here, we assessed the expression of IL-33 and related molecules in the salivary glands (SGs) 
of patients with IgG4-RD versus that in patients with Sjögren’s syndrome (SS) and controls. Expression 
of IL-33 and its receptor (ST2) was strongly detected around ectopic germinal centers (GCs) in the SGs 
from patients with IgG4-RD, whereas IL-33 was expressed only in epithelial cells in patients with SS 
and controls. Moreover, IL-33 and CD68+/CD163+ macrophages were mainly distributed around ectopic 
GCs in patients with IgG4-RD. Double immunofluorescence staining showed that IL-33 expression co-
localized with CD68+/CD163+ macrophages. Finally, mRNA expression levels of IL-33 showed a positive 
correlation to those of Th2 cytokines (IL-4 and IL-13) in patients with IgG4-RD. Our data suggest that 
IL-33 produced by M2 macrophages might contribute to the pathogenesis of IgG4-RD via aberrant 
activation of Th2 immune responses.
Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a recently recognized inflammatory disorder that com-
prises many autoimmune diseases such as type I autoimmune pancreatitis (AIP) and retroperitoneal fibrosis. 
IgG4-RD is characterized by elevated serum IgG4, as well as sclerosing, severe fibrosis, and IgG4-positive cell 
infiltration in affected organs1, which include the lacrimal gland (LG), submandibular gland (SMG), kidney, 
bile ducts, pancreas, prostate and mammary glands. Affected tissues can be diagnosed using comprehensive 
IgG4-related disease or organ-specific diagnostic criteria2.
Mikulicz’s disease (MD) and Küttner tumor (KT) affect the oral maxillofacial region, presenting with changes 
in facial appearance, such as persistent swollen of upper eyelids, parotid gland, and submandibular glands. Owing 
to histopathological similarities, MD is considered a subtype of Sjögren’s syndrome (SS)3; however, Yamamoto et al. 
reported that patients with MD and IgG4-RD share many clinical and pathological characteristics4. Thus, MD 
has been regarded as an IgG4-RD, specifically referred to as IgG4-related dacryoadenitis and sialoadenitis 
(IgG4-DS)5. Our previous data demonstrated that upregulation of helper type 2 (Th2), but not Th1, is important 
in IgG4-DS6,7. In addition, we previously identified that Th2-derived cytokines such as interleukin (IL)-4, IL-10, 
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and IL-21 contribute to the pathogenesis of IgG4-DS, specifically facilitating the production of IgG4 and forma-
tion of ectopic germinal centers7,8. It should be noted that the abovementioned studies were conducted on salivary 
glands (SGs) from patients with IgG4-DS; however, the SG samples from these patients have high frequencies 
of typical IgG4-RD characteristics and are indicated as an ideal pathological manifestation of IgG4-RD9,10. 
Together, these studies have revealed that the main pathogenesis of IgG4-RD is related to Th2 cell and cytokine 
activation11,12.
To our knowledge, no published reports have investigated the mechanism of Th2 cell activation in IgG4-RD. 
Recently, IL-33, a member of the IL-1 cytokine family, has been shown to accelerate Th2 cell expression of the 
IL-33 receptor, ST213. In vitro, IL-33 directly stimulates Th2 cells, mast cells, eosinophils, and basophils, resulting 
in Th2 cytokine production14. Several studies have reported that IL-33 has important biological functions in sev-
eral immune-mediated diseases such as asthma, allergic rhinitis, cardiovascular disease, multiple sclerosis, rheu-
matoid arthritis, and SS15–19. Moreover, IL-33 is produced by epithelial cells, macrophages, dendritic cells (DCs), 
and mast cells13. In humans, at least two types of macrophages and DCs have been identified based on their 
function and reaction. The macrophages include the classically activated macrophage (M1), which is activated via 
CD68+ CD163−, and the alternatively activated macrophage (M2), which is activated via CD68+ CD163+20. The 
DCs include myeloid DC (mDC), which is activated by CD11chigh CD123low, and plasmacytoid DC (pDC), which 
is activated by CD11c− CD123high 21.
Recent reports have indicated that the M1 macrophage is capable of stimulating the Th1 response via IL-6 
and IFN-γ . Alternatively, the M2 macrophage is stimulated by the Th2 response, and promotes the Th2 reaction 
through IL-13 production22,23. Further, mDCs likely exert inhibitory effects on the development of Th1 inflam-
matory responses, while pDCs inhibit Th2 inflammatory responses24. However, the relationship between mac-
rophages, DCs, and IgG4-RD has not yet been elucidated. Therefore, to clarify the contribution of IL-33 to the 
pathogenesis of IgG4-RD, we examined infiltrating cells expressing IL-33 in SGs from patients with IgG4-RD.
Materials and Methods
Ethics Statement. The study design and methods were approved by the Institutional Review Board of 
Center for Clinical and Translational Research of Kyushu University Hospital (IRB serial number: 25–287). The 
methods were carried out in accordance with the approved guidelines. All patients or their relatives gave their 
informed consent within written treatment contract on admission and therefore prior to their inclusion in the 
study.
Study Participants. SG samples were collected from patients referred to the Department of Oral and 
Maxillofacial Surgery, Kyushu University Hospital between 2010 and 2014. Seven patients with IgG4-RD (five 
men and two women; mean age ± standard deviation (SD), 61.7 ± 12.1 years), 10 with primary SS (five men and 
five women; 55.6 ± 20.5 years), and 10 with oral squamous cell carcinoma (OSCC) as a control group (five men 
and five women; 58.4 ± 16.3 years) participated in this study. Clinical and serological profiles of patients with 
IgG4-RD are listed in Table 1.
Patients with IgG4-RD and SS underwent open SG biopsies, as described by Moriyama et al.20, while patients 
with OSCC underwent a neck dissection. SGs from patients with OSCC were histologically normal and exhibited 
no clinical evidence of metastasis. IgG4-RD were diagnosed according to both the “Comprehensive diagnostic 
criteria for IgG4-related disease”2 and “Diagnostic criteria for IgG4-DS”4. All patients with IgG4-RD showed 
characteristic histopathological findings including marked infiltration of IgG4-positive plasma cells, severe fibro-
sis, and formation of multiple ectopic GCs, and had never been treated with steroids or any other immunosup-
pressants. SS was diagnosed according to both the Research Committee on SS of the Ministry of Health and 
No. Age Sex
Disease 
Duration Complications
Swollen glands
Histological 
findings
Complaint Gum test
Saxon 
test
Serological tests
IgG4/
IgG
IgG4+ 
cells RF
ANA
IgG IgG4 IgA IgE IgM
Anti-
SSA
Anti-
SSB
LG PG SMG SLG PLG LSG (%) (/HPF)
Dry 
eye
Dry 
mouth (ml/10 min) (g/2 min) (U/ml) (mg/dl) (mg/dl) (mg/dl)
(U/
ml) (mg/dl)
(U/
ml)
(U/
ml)
1 69 M 3 M HT + − + + − + 61.2 32 − − 6.0 1.8 ND ± 1663 458 97 60 79 − − 
2 68 F 9 M AIP − − + + − + 52.3 42 − − 6.0 2.2 5 160 6758 1500 78 13 81 − − 
3 39 M 2 Y pollinosis + − + − − + 64.2 77 − − 16.4 4.7 5 − 1534 188 170 1619 99 − − 
4 69 M 4 M AIP − − + + − + 63.2 79 − − 12.0 6.8 ND ND 1675 484 229 283 44 − − 
5 74 M 4 M AIP + − + + − + 50.0 85 − − 10.2 3.8 ND 40 4217 524 177 29 60 − − 
6 58 F 6 M − − − + + − − 73 28 − − 12.0 3.6 4 80 1188 151 193 178 56 − − 
7 55 M 3 Y AIP, rectal cancer + − + + − − 70 18 − − 7.4 3.2 4 − 2092 510 148 ND 70 − − 
Table 1. Clinical and serological findings of seven patients with IgG4-related disease (IgG4-RD). 
Abbreviations: LG, lachrymal gland; PG, parotid gland; SMG, submandibular gland; SLG, sublingual gland; 
PLG, palatine gland; LSG, labial salivary gland; HPF, high power field; RF, rheumatoid factor; ANA, antinuclear 
antibody; HT, hyper tension; AIP, autoimmune pancreatitis; + , positive; − , negative; ND, not done; bold italics 
indicate higher than normal values.
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Welfare of the Japanese Government (1999)25 and the American-European Consensus Group criteria for SS26. 
All patients with SS had lymphocytic infiltration in the LSGs, had no other autoimmune diseases, and had never 
been treated with steroids or any other immunosuppressants. There was no documented history of HIV, HTLV-1, 
hepatitis B virus or hepatitis C virus infection in any of the patients. None of the patients had evidence of malig-
nant lymphoma at the time of the study
Immunohistochemical analysis. For immunohistochemical analysis, 4 μ m formalin-fixed, 
paraffin-embedded SG sections were prepared and stained by a conventional avidin–biotin complex technique, 
as previously described7. Anti-ST2, -CD11c, -IL-4, and -IL-13 rabbit polyclonal antibodies were used to analyze 
ST2 (clone: HPA007406, Atlas, Stockholm), CD11c (clone: ab52632; Abcam, USA), IL-4 (clone: ab9622; Abcam, 
USA), and IL-13 (clone: HPA042421, Atlas, Stockholm) cytokines, respectively. Anti-IL-33, -CD68, -CD163, and 
-CD123 mouse monoclonal antibodies were used to analyze IL-33 (clone: Nessy-1, Enzo, Japan), CD123 (clone: 
NCL-CD123, Leica Biosystems, Germany), CD68 (clone: ab955; Abcam, USA), and CD163 (clone: NCL-CD163, 
Leica Biosystems, Germany) molecules, respectively. Sections were stained and evaluated according to previously 
described methods27.
Double immunofluorescence of IL-33 and cell markers in SGs from patients with IgG4-RD. For 
double immunofluorescence analysis, 4 μ m formalin-fixed and paraffin-embedded SGs from patients with 
IgG4-RD were prepared and stained. Sections were incubated with the primary antibody, IL-33 (Enzo), at room 
temperature for 2 h after blocking with 1% BSA blocking buffer for 1 h. Sections were then incubated with the 
secondary antibody, Alexa 488® (1:100 dilution, Abcam, USA), for 30 min and washed well while avoiding light. 
Sections were blocked in 1% BSA blocking buffer for 40 min and then incubated with the primary antibodies 
against CD68 (Abcam), CD163 (clone: EDHu-1, AbD Serotec, USA), CD11c (Abcam), or CD123 (Leica) at room 
temperature for 2 h. After incubation, sections were incubated in Alexa 568® secondary antibody (1:100 dilution, 
Abcam, USA) for 30 min at room temperature, washed well while avoiding light, mounted in VECTASHIELD® 
with DAPI for nuclei staining (Vector Laboratories, USA), and stored in the dark. Images were taken using a 
Keyence microscope (BZ-9000 series) with the background fluorescence level set using negative controls as no 
detected nuclei.
RNA extraction and complementary DNA (cDNA) synthesis. Total RNA was prepared from SGs by 
the acidified guanidinium–phenol–chloroform method as previously described7,28. One microgram of the total 
RNA preparation was then used for the synthesis of cDNA. Briefly, RNA was incubated for 1 h at 42 °C with 20 
U of RNasinribonuclease inhibitor (Promega, Madison, WI, USA), 0.5 μ g of oligo-1218 (Pharmacia, Uppsala, 
Sweden), 0.5 mM of each deoxyribonucleotide triphosphate (dNTP) (Pharmacia), 10 mM of dithiothreitol (DTT), 
and 100 U of RNase Reverse Transcriptase (Life Technologies, Gaithersburg, MD, USA).
Quantitative estimation of mRNA by real-time PCR. mRNA levels of the cytokines and chemokines 
in SGs were quantified by real-time PCR, using Light Cycler Fast Start DNA Master SYBR Green III (Roche 
Diagnostics, Mannheim, Germany) in a Light Cycler real-time PCR instrument (version 3.5; Roche Diagnostics). 
In this study, the cytokines and cluster of differentiations were IL-33, ST2, IL-4, IL-13, CD68, CD163, CD11c, and 
CD123. Target mRNA levels were expressed relative to β -actin as the housekeeping gene. The primer sequences 
used were as follows: β -actin, forward 5′ -GCA AAG ACC TGT ACG CCA AC-3′ , reverse 5′ -CTA GAA GCA 
TTT GCG GTG GA-3′ , 260 bp; IL-33, forward 5′ -ATG AGT CTC AAC ACC CCT CAA-3′ , reverse 5′ -CTG GTC 
TGG CAG TGG TTT TT-3′ , 155 bp; ST2 forward 5′ -ATT TGC ATG GCT TGA GAA GG-3′ , reverse 5′ -AGA 
GAA GCT CCC AGC AAA CA-3′ , 240 bp; IL-4 forward 5′ -AGC TGA TCC GAT TCC TGA AAC-3′ , reverse 
5′ -TAC TCT GGT TGG CTT CCT TCA C-3′ , 90 bp; IL-13 forward 5′ -GGT CAA CAT CAC CCA GAA CC-3′ , 
reverse 5′ -TTT ACA AAC TGG GCC ACC TC-3′ , 240 bp; CD68 forward 5′ -TCA GAA TGC ATC CCT TCG 
AG-3′ , reverse 5′ -GAT GAG AGG CAG CAA GAT GG-3′ , 199 bp; CD163 forward 5′ -TGA TT CGG ACT TCT 
CTC TGG-3′ , reverse 5′ -ACT GGG CAG AGT GAA AGA TG-3′ , 168 bp; CD11c forward 5′ -TAC CTC ACC 
GGA CTC TGC TT-3′ , reverse 5′ -GGA GAA CTG CAT CAG GGA AA-3′ , 228 bp; CD123 forward 5′ -CCC 
AAC ATG ACT GCA AAG TG-3′ , reverse 5′ -CTA GAA GCA TTT GCG GTG GA-3′ , 200 bp. All analyses were 
performed in triplicate.
Cytokine determination by enzyme-linked immunosorbent assay (ELISA). IL4, IL-13, and IL-33 
were measured by ELISA (IL-4: ab181426; Abcam, IL-13: ab178014; Abcam, and IL-33: GWB-SKR038; Gen Way 
Biotech, USA), according to the manufacturer’s protocol. These results were compared with 12 non-smoking 
volunteers (healthy controls) who had no sicca or clinical or laboratory evidence of systemic disease. All analyses 
were performed in triplicate.
Statistics. Statistical significance of the differences between groups was determined using the following 
methods. A Mann-Whitney U test was used when populations were not normally distributed in the detection of 
mRNA expression levels7,28. A non-parametric Spearman test was used for the correlation analysis. All statistical 
analyses were performed with JMP software, version 8 (SAS Institute, Cary, NC, USA). A P value less than 0.05 
was considered statistically significant.
Results
Expression of IL-33, ST2, and Th2 cytokines in SGs. The mRNA expression levels of IL-33, ST2, and 
IL-4 in SGs from patients with SS and IgG4-RD were significantly higher than those in controls. Furthermore, the 
mRNA levels of ST2, IL-4, and IL-13 in patients with IgG4-RD were significantly higher than those from patients 
with SS (Fig. 1A). The relationships between mRNA expression levels of IL-33 and Th2 cytokines (IL-4, IL-13) in 
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Figure 1. The expression of IL-33 and related molecules was higher in patients with IgG4-related disease 
(IgG4-RD). (A) mRNA expression levels of IL-33 and related molecules was examined in salivary glands (SGs) 
from controls (n = 10), and patients with Sjögren’s syndrome (SS) (n = 10) and IgG4-RD (n = 7). Molecules 
were quantitatively estimated as described in the Methods section, and significant differences between groups 
were determined by the Mann–Whitney U test (*p < 0.05, **p < 0.01). (B) Correlation between mRNA 
expression levels of IL-33 and related molecules in SGs from controls, as well as patients with SS and IgG4-RD. 
Statistical significance of differences between groups was determined by Spearman’s rank correlation (p < 0.05). 
(C) Distribution of IL-33 and related molecules in SGs from representative controls and patients with SS and 
IgG4-RD. Counterstaining was performed with Mayer’s hematoxylin (blue). IL-33 positive ductal epithelial cells 
are indicated by block arrows, while IL-33 positive cells are indicated by yellow arrows. Scale bars, 100 μ m.
www.nature.com/scientificreports/
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SGs were examined, and the mRNA expression of IL-33 was positively correlated with Th2 cytokines in SGs from 
patients with IgG4-RD but not with Th2 cytokines in SGs from patients with SS and controls (Fig. 1B). To eval-
uate the distribution of IL-33, ST2, and Th2 cytokines, representative histological findings in the SG specimens 
from patients with SS and IgG4-RD and from controls are shown in Fig. 1C. Expression of IL-33 was detected in 
all samples in the ductal epithelial cells, identified morphologically and indicated by black arrows. Interestingly, 
IL-33 was also detected in infiltrating lymphocytes around ectopic germinal centers (GCs) in patients with 
IgG4-RD, as indicated by yellow arrows in Fig. 1C. Expression of ST2, IL-4, and IL-13 was detected in infiltrating 
lymphocytes around ectopic GCs from patients with SS and IgG4-RD, but not in controls. In addition, patients 
with IgG4-RD showed strong infiltration of these positive cells in comparison to patients with SS.
Expression of IL-33-producing cells in SGs. As IL-33 is considered to be produced by epithelial 
cells and antigen-presenting cells (APCs), such as macrophages and DCs13, we examined the expression of 
IL-33-producing cells in SGs from patients with SS and IgG4-RD, as well as in controls. The mRNA levels of 
CD68, CD163, CD11c, and CD123 were significantly higher in patients with IgG4-RD than in the two other 
evaluated groups (Fig. 2A). Specimens were also immunohistochemically examined to clarify the distribution 
of IL-33-producing cells, including macrophagess (CD68, CD163), and DCs (CD11c, CD123), in the SGs from 
patients with SS and IgG4-RD, as well as controls. Expression of CD68 and CD163 was strongly detected around 
Figure 2. Expression and localization of innate immune cells in SGs. (A) mRNA expression levels of innate 
immune cells in SGs from controls (n = 10), and patients with SS (n = 10) and IgG4-RD (n = 7). Expression 
levels of innate immune cells markers for macrophages (CD68), M2 macrophages (CD163), mDC (CD11c), 
and pDC (CD123) were estimated quantitatively as described in the Methods section. Statistically significant 
differences between groups were determined by Mann–Whitney U tests (*p < 0.05, **p < 0.01). (B) Distribution 
of innate immune cells in SGs from representative controls and patients with SS and IgG4-RD. Counterstaining 
was performed with Mayer’s hematoxylin (blue). Scale bars, 100 μ m.
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ectopic GCs in SGs from patients with IgG4-RD, whereas CD68 and CD163 were detected around ductal epi-
thelial cells in patients with SS. Expression of CD11c was strongly detected in/around ectopic GCs in patients 
with IgG4-RD, whereas CD11c was detected around ductal epithelial cells in patients with SS. Finally, expression 
of CD123 was slightly detected in/around ectopic GCs in patients with IgG4-RD, but CD123 was rarely seen in 
patients with SS. All of these markers were rarely seen in controls (Fig. 2B).
Co-localization of IL-33 and cell markers in SGs from patients with IgG4-RD. To clarify which 
cells produced IL-33, double immunofluorescence staining with IL-33 (green) and CD68, CD163, CD11c, or 
CD123 (red) was performed. Using this approach, we observed that IL-33-positive cells co-localized with CD68- 
and CD163-positive cells, indicated by white arrows, and only partly co-localized with CD11c- or CD123-positive 
cells (Fig. 3). Therefore, macrophages, especially M2 macrophages, might be responsible for the production of 
IL-33 in SGs from patients with IgG4-RD.
Serum concentration of IL-33 and Th2 cytokines. Recent study reported that serum IL-33 and ST2 
were significantly elevated in pSS patients in comparison with healthy controls18. Therefore, we measured the 
serum concentration of IL-33 and Th2 cytokines (IL-4 and IL-13) in patients with SS, IgG4-RD, and healthy con-
trols by ELISA. Serum IL-33 levels in patients with pSS were higher than that in controls (Fig. 4A), and IgG4-RD 
showed the decrease in serum IL33 after steroid therapy (Fig. 4B). On the other hand, there was no significant 
difference in serum IL-4 and IL-13 levels between IgG4-RD patients and controls (Supplementary Figure 1).
Discussion
IgG4-RD is well known as a systemic disorder that is characterized by elevated serum IgG4, marked infiltration 
of IgG4-positive plasma cells, and severe fibrosis with hyperplastic eGCs in affected lesions. Although many basic 
studies on IgG4-RD have been reported in the past 10 years, the pathogenic mechanism of the disease remains 
unclear. Recent studies have reported that IgG4-RD is a Th2-dominant disease and that aberrant activation of the 
Th2 immune response plays a key role in its pathogenesis6–8,29,30. In this study, we focused on IL-33 as a recently 
identified cytokine that enhances Th2 cytokine production.
Figure 3. M2 macrophages produce IL-33 in SGs from patients with IgG4-RD. Double immunofluorescence 
staining performed with IL-33 (green), innate immune cells markers for macrophages (CD68), M2 
macrophages (CD163), mDC (CD11c), and pDC (CD123) (red), and DAPI for nuclei staining (blue), as 
described in the Methods section. Scale bars, 50 μ m.
www.nature.com/scientificreports/
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Recent studies indicated the involvement of the IL-33/ST2 axis in the pathogenesis of pSS18,19. They found 
that serum IL-33 and ST2 levels were increased in pSS patients and that IL-33 producing cells were mainly epi-
thelial cells in SGs from patients with pSS. Our current data were consistent with these previous reports, and 
reveal that expression of IL-33 in SGs from patients with IgG4-RD was detected not only in ductal epithelial 
cells, but also around ectopic GCs. It is found that IL-33 was mainly expressed in epithelial cells and produced 
by a wide variety of cell types including DCs, macrophages, fibroblasts, mast cells, and osteoblasts31. Here, to 
confirm the IL-33-producing cells around ectopic GCs, we analyzed the expression of macrophages and DCs 
and found that IL-33 could be localized to M2 macrophages. In addition, mRNA expression of IL-33 was posi-
tively correlated with that of Th2 cytokines in patients with IgG4-RD. These results indicate that the majority of 
IL-33-producing cells in IgG4-RD might be M2 macrophages, which are deeply involved in the activation of Th2 
immune responses.
With regard to DCs, recent studies that pDCs in SGs ware associated with the pathological processes of acute/
chronic salivary inflammation in SS and IgG4-RD32,33. In our current study, we found that IL-33-positive cells 
partly co-localized with CD11c- or CD123-positive DCs in SGs from patients with IgG4-RD, but IL-33 and DCs 
were rarely seen in SS. Maria NI, et al.34 divided pSS patients according to the mRNA expression of IFN type I 
in PBMC, and demonstrated that pDCs were detected in SGs from only IFN-positive pSS. Considering to these 
reports, our current data (Fig. 2B) might be reflect to the results of IFN-negative pSS.
We previously examined M1 and M2 macrophage subsets in SGs from patients with SS, chronic sialoadenitis, 
and IgG4-RD, and indicated that the amount and frequency of M2 macrophages in patients with IgG4-RD were 
significantly higher than those in controls, as well as in patients with chronic sialoadenitis and SS. These findings 
were mirrored by other lesions in the LG, pancreas, pleura, and prostate gland from patients with IgG4-RD27. 
Furthermore, Fukui et al.35 detected M2 macrophages expressing toll-like receptor 7 (TLR7) in patients with 
IgG4-related autoimmune pancreatitis. Alveolar macrophages are the primary source of increased IL-33 levels 
during infection, and an in vitro stimulation of these cells with a TLR7 agonist induces IL-33 expression36. In the 
current study, we also detected a number of SGs expressing TLR7 from patients with IgG4-RD. Further, these 
SGs were shown to co-localize with CD163-positive cells (Supplemental Fig. 2), indicating that M2 macrophages 
activated by the TLR7 pathway might play a crucial role in IgG4-RD as well as IgG4-related AIP.
In our previous study, gene expression in SGs from patients with IgG4-RD, chronic sialoadenitis and controls 
was analyzed via DNA microarrays. Using this approach, the macrophage receptor with collagenous structure 
(MARCO), one of the scavenger receptors37, was identified as a disease-associated molecule in patients with 
IgG4-RD. Moreover, immunohistochemical analysis has confirmed that the expression patterns of MARCO are 
similar to those of M2 macrophage marker CD16310. MARCO, a scavenger receptor expressed by macrophages38, 
has been reported to play an important role in the innate immune response by mediating ligand binding and 
phagocytosis. Further, this receptor can recognize various ligands including bacterial lipopolysaccharide (LPS), 
apoptotic cells, lung pathogens, environmental particles, and nanomaterials39.
Taken together with the previous reports, the current results indicate that M2 macrophages may contribute to 
the initiation or maintenance of IgG4-RD via IL-33 production. We thus made the following hypothesis regarding 
the pathogenic process in IgG4-RD: M2 macrophages recognize certain exogenous or endogenous molecules 
through binding to pattern-recognition receptors, including TLR7 and MARCO. Following their binding to these 
receptors, M2 macrophages promote the production of IL-33, which precipitates an exaggerated Th2 immune 
responses and the pathology noted in IgG4-RD (Supplementary Figure 3).
On the other hand, other Th subsets (regulatory T cells, T follicular helper (Tfh) cells, and CD4+ cytotoxic 
T lymphocytes) and innate immune cells (DCs and basophils) have recently received increasing attention with 
regard to the pathogenesis of IgG4-RD29,40,41. Maehara T, et al.42 reported that the ratio of CD4+ GZMA+ CTLs 
in SMGs from patients with IgG4-DS correlated with serum IgG4 concentrations and the number of affected 
Figure 4. Serum concentration of IL-33. (A) Serum levels of IL-33 were measured in healthy controls 
(n = 12), and patients with SS (n = 10) and IgG4-RD (n = 7). (B) Serum levels of IL-33 were measured in 6 
patients with IgG4-RD who were treated by corticosteroid after final diagnosis. Significant differences between 
groups were determined by the Mann–Whitney U test (*p < 0.05).
www.nature.com/scientificreports/
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organs. Therefore, IgG4-RD might be initiated and progressed by the interconnected network of various Th sub-
sets. A literature Summary on the etiology and pathogenesis of IgG4-DS and SS is shown in Table 2.
In conclusion, we confirmed IL-33 overexpression in M2 macrophages clustered around ectopic GCs in 
SGs from patients with IgG4-RD. However, functional assays are needed to elucidate the mechanism of M2 
macrophage-mediated IL-33 production. Although glucocorticoids are effective and the standard treatment for 
IgG4-RD, Yamamoto et al.43 reported that almost half of patients with IgG4-RD experience disease relapse during 
long-term steroid therapy. A more thorough understanding of the role of M2 macrophages in IgG4-RD could lead 
to the establishment of a mouse model of IgG4-RD and to the eventual development of novel pharmacological 
strategies to interrupt IL-33/ST2 signaling as a further means of inhibiting disease initiation or progression.
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